Assembly Biosciences (ASMB) Receivables (2017 - 2026)

Assembly Biosciences (ASMB) posted quarterly Receivables of $451000.0 for Q1 2026, down 53.7% quarter-over-quarter from $974000.0 in Q4 2025.

Assembly Biosciences (ASMB) Receivables (2017 - 2026) Analysis & Trends

Assembly Biosciences' Receivables history runs 10 years deep, the most recent figure standing at $451000.0 for Q1 2026.

In Q1 2026, Receivables changed N/A year-over-year to $451000.0; the TTM figure through Mar 2026 stood at $451000.0 (changed N/A YoY), while the FY2025 annual figure was $974000.0, changed N/A from the prior year.
Receivables for Q1 2026 stood at $451000.0, down from $974000.0 in the prior quarter.
The five-year high for Receivables was $1.2 million in Q3 2022, with the low at $43000.0 in Q4 2023.
The 5-year median for Receivables is $524000.0 (2022), against an average of $610818.2.
The sharpest annual moves came in 2022 and 2023: Receivables soared 180.95% in 2022, then tumbled 95.44% in 2023.
Assembly Biosciences' Receivables stood at $944000.0 in 2022, then sank by 95.44% to $43000.0 in 2023, then changed by 0.0% to $43000.0 in 2024, then surged by 2165.12% to $974000.0 in 2025, then tumbled by 53.7% to $451000.0 in 2026.
Business Quant data shows ASMB's Receivables at $451000.0 in Q1 2026, $974000.0 in Q4 2025, and $912000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	Assembly Biosciences	670.88 Mn	350.52 Mn	-	822,000.00

Download Data